Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

Sangamo price target raised to $34 from $24

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ciciagt Member Profile
Member Level 
Followed By 20
Posts 2,229
Boards Moderated 0
Alias Born 01/02/03
160x600 placeholder
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer Business Wire - 9/30/2019 4:15:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 9/30/2019 8:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/26/2019 6:16:05 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/30/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:11:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:05:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:45:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:38:07 PM
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results Business Wire - 8/7/2019 4:01:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/6/2019 4:05:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/6/2019 4:03:48 PM
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel Business Wire - 7/31/2019 4:15:00 PM
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast Business Wire - 7/31/2019 4:05:00 PM
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases Business Wire - 7/29/2019 11:00:00 AM
Sangamo et Pfizer annoncent des résultats de phase 1/2 mis à jour pour la thérapie génique expérimentale de l’hémoph... Business Wire - 7/8/2019 10:05:00 AM
Sangamo Therapeutics Up 17%; Unveiled Updated Study Data Dow Jones News - 7/8/2019 8:43:00 AM
Sangamo & Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained In... Business Wire - 7/5/2019 11:15:00 PM
 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger P... Business Wire - 7/1/2019 11:00:00 AM
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire (US) - 6/21/2019 9:16:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/18/2019 5:03:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
ciciagt Member Level  Tuesday, 04/02/19 10:50:50 AM
Re: jessellivermore post# 323
Post # of 340 
Sangamo price target raised to $34 from $24 at Wells Fargo. Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.

Read more at:
https://thefly.com/landingPageNews.php?id=2887507

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist